Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

A catalyst system includes a transition metal salt containing a halo group, an acetate group, or a combination thereof, and an organic phosphine ligand. The molar ratio of the organic phosphine ligand to the transition metal salt is greater than 0 and less than or equal to 50.

A catalyst system includes a transition metal salt containing a halo group, an acetate group, or a combination thereof, and an organic phosphine ligand. The molar ratio of the organic phosphine ligand to the transition metal salt is greater than 0 and less than or equal to 50.

Provided is a non-aqueous electrolyte for lithium ion battery, comprising a compound A represented by structural formula I and a compound B represented by structural formula II: ##STR00001##
Wherein, in formula I, R.sub.1 is selected from alkylene having 1-5 carbon atoms or fluorine substituted alkylene having 1-5 carbon atoms; R.sub.2 is selected from anyone of alkylene having 1-5 carbon atoms, fluorine substituted alkylene having 1-5 carbon atoms or carbonyl; In formula II, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each independently selected from hydrogen, fluorine atom or a group containing 1-5 carbon atoms. The compound A and compound B of the non-aqueous electrolyte can form a passivation film formed by reduction, decomposition and combination reactions on the surface of negative electrode material of lithium-ion battery, thereby improving thermal stability of the passivation film and high-temperature cycle and storage performance of the battery.

Provided is a non-aqueous electrolyte for lithium ion battery, comprising a compound A represented by structural formula I and a compound B represented by structural formula II: ##STR00001##
Wherein, in formula I, R.sub.1 is selected from alkylene having 1-5 carbon atoms or fluorine substituted alkylene having 1-5 carbon atoms; R.sub.2 is selected from anyone of alkylene having 1-5 carbon atoms, fluorine substituted alkylene having 1-5 carbon atoms or carbonyl; In formula II, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7 and R.sub.8 are each independently selected from hydrogen, fluorine atom or a group containing 1-5 carbon atoms. The compound A and compound B of the non-aqueous electrolyte can form a passivation film formed by reduction, decomposition and combination reactions on the surface of negative electrode material of lithium-ion battery, thereby improving thermal stability of the passivation film and high-temperature cycle and storage performance of the battery.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.

Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can be then removed under mild conditions to generate the target oligonucleotide in high purity.

Compounds and methods for purifying oligonucleotides such as RNA and DNA. A target oligonucleotide is reacted with an orthoester linker comprising an affinity tag to form an orthoester oligonucleotide-orthoester linker conjugate which is subjected to a purification technique to separate the target oligonucleotide from impurities such as truncated oligonucleotides. The orthoester linker can be then removed under mild conditions to generate the target oligonucleotide in high purity.

Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.